It is possible, if you lay the groundwork, to provide patients with acute leukemias with aggressive and effective therapies, while still allowing them to maintain quality of life, explained Jennifer Vaughn, MD, of The Ohio State University Comprehensive Cancer Center – James Cancer Hospital.
Typically, patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) receive aggressive chemotherapy treatment that requires long hospital stays, but it is possible to put the foundation in place for these patients to receive support in the outpatient setting in order for them to maintain quality of life and remain close to the people who matter to them, explained Jennifer Vaughn, MD, of The Ohio State University Comprehensive Cancer Center – James Cancer Hospital.
Transcript
Your earlier research has shown the benefits of early discharge to an outpatient setting after intensive chemotherapy for AML or MDS. Does this still hold true? And how can value-based care enhance this practice?
So that was a study that I participated in during my fellowship at the University of Washington Fred Hutch Cancer Center. And yes, I absolutely do think that its findings are relevant, primarily because the patients with acute leukemias who are eligible to receive higher doses of chemotherapy or attempt the curative therapy, still, the treatment remains the same: it's still very high doses of chemo followed often—at most institutions—by a very prolonged hospital stay. As you can imagine, this really influences the mental health and quality of life of a patient who is not only now dealing with a new very serious cancer diagnosis and the side effects of their treatment, but also become very isolated from things that they love to do on a daily basis. It becomes more difficult for them to see the people that they like to spend time with. In addition to that, it becomes very hard on the caregivers as well.
The goal of that study was to try to provide patients with equivalent, aggressive, and effective care but also allow them to improve their overall experience in the posttreatment setting. I think that is something we should always be striving to do but do it in a safe manner. As we said in the study, it was extremely important for us to have outpatient resources and supportive care, space, and providers in place in order to provide the much needed supportive therapy that they need after treatments. This should only be done with the greatest thought that goes into laying the groundwork for it ahead of time and knowing that you have the space and resources and expertise to be able to provide it.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen